Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer
Search for other papers by Caitlin A. Hester in
Current site
Google Scholar
PubMed
Search for other papers by Giampaolo Perri in
Current site
Google Scholar
PubMed
Search for other papers by Laura R. Prakash in
Current site
Google Scholar
PubMed
Search for other papers by Jessica E. Maxwell in
Current site
Google Scholar
PubMed
Search for other papers by Naruhiko Ikoma in
Current site
Google Scholar
PubMed
Search for other papers by Michael P. Kim in
Current site
Google Scholar
PubMed
Search for other papers by Ching-Wei D. Tzeng in
Current site
Google Scholar
PubMed
Search for other papers by Brandon Smaglo in
Current site
Google Scholar
PubMed
Search for other papers by Robert Wolff in
Current site
Google Scholar
PubMed
Search for other papers by Milind Javle in
Current site
Google Scholar
PubMed
Search for other papers by Michael J. Overman in
Current site
Google Scholar
PubMed
Search for other papers by Jeffrey E. Lee in
Current site
Google Scholar
PubMed
Search for other papers by Matthew H.G. Katz in
Current site
Google Scholar
PubMed
Background: This study aimed to determine the clinical relevance of putative radiographic and serologic metrics of chemotherapy response in patients with localized pancreatic cancer (LPC) who do not undergo pancreatectomy. Studies evaluating the response of LPC to systemic chemotherapy have focused on histopathologic analyses of resected specimens, but such specimens are not available for patients who do not undergo resection. We previously showed that changes in tumor volume and CA 19-9 levels provide a clinical readout of histopathologic response to preoperative therapy. Methods: Our institutional database was searched for patients with LPC who were treated with first-line chemotherapy between January 2010 and December 2017 and did not undergo pancreatectomy. Radiographic response was measured using RECIST 1.1 and tumor volume. The volume of the primary tumor was compared between pretreatment and posttreatment images. The percentage change in tumor volume (%Δvol) was calculated as a percentage of the pretreatment volume. Serologic response was measured by comparing pretreatment and posttreatment CA 19-9 levels. We established 3 response groups by combining these metrics: (1) best responders with a decline in %Δvol in the top quartile and in CA 19-9, (2) nonresponders with an increase in %Δvol and in CA 19-9, and (3) other patients. Results: This study included 329 patients. Individually, %Δvol and change in CA 19-9 were associated with overall survival (OS) (P≤.1), but RECIST 1.1 was not. In all, 73 patients (22%) were best responders, 42 (13%) were nonresponders, and there were 214 (65%) others. Best responders lived significantly longer than nonresponders and others (median OS, 24 vs 12 vs 17 months, respectively; P<.01). A multivariable model adjusting for type of chemotherapy regimen, number of chemotherapy doses, and receipt of radiotherapy showed that best responders had longer OS than did the other cohorts (hazard ratio [HR], 0.35; 95% CI, 0.21–0.58 for best responders, and HR, 0.55; 95% CI, 0.37–0.83 for others). Conclusions: Changes in tumor volume and serum levels of CA 19-9—but not RECIST 1.1—represent reliable metrics of response to systemic chemotherapy. They can be used to counsel patients and families on survival expectations even if pancreatectomy is not performed.
Submitted September 20, 2021; final revision received March 1, 2022; accepted for publication April 14, 2022.
Disclosures: Dr. Javle has disclosed serving on the data safety monitoring board for Oncosil and Incyte; and has served as a scientific advisor for Bristol Myers Squibb, Merck, QED Therapeutics, Helsinn, EMD Serono, Incyte, Taiho, Servier, AstraZeneca, Genentech, Zymeworks, Transthera, Meclun, Bayer, Novartis, and Boehringer Ingelheim. Dr. Overman has disclosed receiving grant/research support from Roche, Takeda, Merck & Co., Bristol Myers Squibb, AstraZeneca, and Nouscom; and serving as a consultant for Phanes Therapeutics, Takeda Pharmaceuticals, Ipsen Biopharmaceuticals, Pfizer, Merck & Co., GlaxoSmithKline, Promega, 3D Medicine, Nouscom, Gritstone, Tempus, and Roche. The remaining authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.
Supplementary Materials
- Supplemental Materials (PDF 564 KB)
© 2019-2024 National Comprehensive Cancer Network